Expanded Basal Insulin Options
نویسندگان
چکیده
منابع مشابه
Review of basal‐plus insulin regimen options for simpler insulin intensification in people with Type 2 diabetes mellitus
AIMS To identify simple insulin regimens for people with Type 2 diabetes mellitus that can be accepted and implemented earlier in primary and specialist care, taking into consideration each individual's needs and capabilities. METHODS Using randomized clinical trials identified by a search of the PubMed database, as well as systematic reviews, meta-analyses and proof-of-concept studies, this ...
متن کاملInsulin Degludec, The New Generation Basal Insulin or Just another Basal Insulin?
The advances in recombinant DNA technology have led to an improvement in the properties of currently available long-acting insulin analogs. Insulin degludec, a new generation ultra-long-acting basal insulin, currently in phase 3 clinical trials, has a promising future in clinical use. When compared to its rival basal insulin analogs, a longer duration of action and lower incidence of hypoglycem...
متن کاملNonsurgical Treatment Options for Basal Cell Carcinoma
Basal cell carcinoma (BCC) remains the most common form of nonmelanoma skin cancer (NMSC) in Caucasians, with perhaps as many as 2 million new cases expected to occur in the United States in 2010. Many treatment options, including surgical interventions and nonsurgical alternatives, have been utilized to treat BCC. In this paper, two non-surgical options, imiquimod therapy and photodynamic ther...
متن کاملNew options in insulin therapy.
OBJECTIVE To review the new options in insulin therapy for controlling diabetes mellitus in children and adolescents. SOURCES Articles indexed in PubMed were located using the search terms insulin analogs in children and adolescents and reviewed. Information was also obtained from American Diabetes Association and Sociedade Brasileira de Diabetes consensus documents. SUMMARY OF THE FINDINGS...
متن کاملModafinil: expanded options for the treatment of excessive sleepiness
10.2217/14750708.2.2.191 © 2 part of Modafinil is an oral wake-promoting agent, initially approved in December 1998 for the treatment of excessive sleepiness associated with narcolepsy. Based on the results of additional randomized, placebo-controlled studies, the indication for modafinil was expanded in January 2004 to include excessive sleepiness associated with obstructive sleep apnea/hypopn...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: The Journal for Nurse Practitioners
سال: 2017
ISSN: 1555-4155
DOI: 10.1016/j.nurpra.2017.02.003